Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31
One-year data from an interim analysis of the OLYMPIA long-term extension (LTE) study show that more than 80% of nemolizumab-treated patients with prurigo nodularis experienced improvement in itch and more than 60% achieved clear or almost-clear skin1
Results from the phase III ARCADIA clinical trials in atopic dermatitis show that nemolizumab-treated patients who responded at 16 weeks maintained skin and itch responses through to week 48, even when dosing was reduced from every four to every eight weeks2
These new data build on results from the phase III OLYMPIA and ARCADIA clinical trial programs and demonstrate nemolizumab’s long-term and long-lasting benefit in prurigo nodularis and atopic dermatitis, respectively1-5
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.1 Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of patients maintained skin and itch responses through to week 48, with similar efficacy observed whether receiving nemolizumab every four (Q4W) or eight weeks (Q8W).2 These late-breaking data are being presented today at the 2024 American Academy of Dermatology Association (AAD) Annual Meeting, taking place on March 8-12, 2024.
|
“We’re excited to see the evidence base for nemolizumab continue to
build and strengthen for these debilitating diseases, where symptoms
such as intense itch can put a significant burden on quality of life.
Having already demonstrated nemolizumab’s efficacy and rapid onset
of action, these new results show its long-term benefit and durability of
response in prurigo nodularis and atopic dermatitis, respectively.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.
GLOBAL HEAD OF R&D
GALDERMA
|
|网站首页|财经金融|银行|股票|基金|保险|期货|股评|港股|美股|外汇|债券|黄金|理财|信托|房产|汽车|
|